Highly active antiretroviral therapy for patients with HIV/HCV co-infection

( views:222, downloads:0 )
Author:
LU Rui-chao(Department of Infectious Diseases, Guangxi Longtan Hospital, Liuzhou 545005, Guangxi Zhuang Autonomous Region, China)
ZHANG Yong(Department of Infectious Diseases, Guangxi Longtan Hospital, Liuzhou 545005, Guangxi Zhuang Autonomous Region, China)
LI Hong-ru(Department of Infectious Diseases, Guangxi Longtan Hospital, Liuzhou 545005, Guangxi Zhuang Autonomous Region, China)
XU Cai-ling(Department of Infectious Diseases, Guangxi Longtan Hospital, Liuzhou 545005, Guangxi Zhuang Autonomous Region, China)
DOU Yan-yun(Department of Infectious Diseases, Guangxi Longtan Hospital, Liuzhou 545005, Guangxi Zhuang Autonomous Region, China)
CAI Wei-ping()
Journal Title:
Chinese Journal of Clinical Infectious Diseases
Issue:
Volume 04, Issue 04, 2011
DOI:
10.3760/cma.j.issn.1674-2397.2011.04.003
Key Word:
Human immunodeficiency virus; Hepatitis C virus; Highly active antiretroviral therapy

Abstract: Objective To investigate the efficacy of highly active antiretroviral therapy (HAART) for HIV/HCV co-infection patients. Methods A randomized and double blinded trial was conducted in sixty-three HIV/HCV co-infected patients ( group A) and 62 HIV infected patients ( group B). The group A (study group) was further divided into A1, A2, A3 subgroups randomly by Spw-Pb network data system, and were given three different HAART regimens based on nevirapine (NVP), efavirenz (EFV) and lopinavir/ritonavir(LPV/r), respectively. CD4+ T lymphocyte counts, HIV virus load, glutamate-pyruvate transaminase (ALT) were detected at baseline and at the endpoint of study (48 weeks). SPSS 13.0 was used for statistical analysis. One-way ANOVA and LSD-t tests were performed. Results After 48 weeks treatment, HIV RNA became negative in 59 patients of group A (59/63, 93.7% ), while that in group B was 61 (61/62, 98.4% ) (x2 =0. 159, P > 0.05 ). CD4+ T lymphocyte count in group A was (208 ± 77 )/μL, which was significantly lower than that in group B (263 ± 78)/μL (t =-2. 759, P = 0. 008 ).ALT level in group A was (57 ±49)U/L, which was significantly higher than in group B (31 ± 14) U/L (t = 2. 027, P = 0.047). CD4 + T lymphocyte count in group A3 was significantly higher than that in A1 (t=-2. 191, P =0.045), while ALT level in A1 was much higher than that in subgroups A2 and A3 ( t = 2.568 and 2.478, P < 0. 05 ). The incurrence of drug-induced hepatitis in HIV/HCV co-infected group was much higher than that in HIV infected group (55.5% vs. 27.4%, x2 = 10. 182, P = 0.001 ).Conclusions HCV co-infection in HIV patients shows no impact on virological response to HAART, but the immunological response is poorer. Hepatotoxicity is common among patients receiving HAART, especially those who are receiving NVP containing regimens. LPV/r based regimens are recommend for HIV/HCV coinfected patients.

  • [1]Sulkowski MS.Viral hepatitis and HIV coinfection.J Hepatol,2008,48(2):353-367.
  • [2]Klenerman P,Kim A.HCV-HIV coinfection:simple messages from a complex disease.PLoS Med,2007,4(10):e240.
  • [3]Lewden C,Salmon D,Morlat P,et al.Causes of deaths among human immunodeficiency virus (HIV) -infected adults in the era of potent antiretroviral therapy:emerging role of hepatitis and cancers,persistent role of AIDS.Int J Epidemiol,2005,34 (1):121-130.
  • [4]中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南.中 华传染病杂志,2006,24(2):133-142.
  • [5]中华医学会肝病学分会,中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南.中华传染病杂志,2004,22(2):131-136.
  • [6]Sulkowski MS,Mehta SH,Torbenson MS,et al.Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults.AIDS,21 (16):2209-2216.
  • [7]马建新,王江蓉,沈银忠,等.上海地区人类免疫缺陷病病毒/艾滋病合并乙型、丙型肝炎病毒感染的临床流行病学研究.微生物与感染,2006,1(4):207-210.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn